Genmab — Marts 2021

[GeorgeBest]

Tak til Helge for at arrangere denne unike mulighed for interaction med JvdW

[E_L]

so I guess we learned there is a maximum to the time JNJ can think about HexaBody-CD38 , which is they 'can in theory wait for the clinical data from two clinical studies'

[E_L]

I don't understand why he didn't give us the Dara price hike; he did so the last 2 times? Maybe there was no hike... Has anyone seen it anywhere else?

[Helge_LarsenPI-redaktør]

Tak GB og tusinde tak til alle for de skarpe spørgsmål. Desværre var der ikke plads til dem alle indenfor tidsrammen.

[Solsen]

CD37 glæder jeg mig også til...

[Bulder]

I morgen kommer der SH-tal. Holder du udkig Helge? Gerne for januar også.

[Solsen]

Masser af potentiale i de stoffer vi kender.

[E_L]

Dara up to 14% of the frontline patients, last time we heard i think
was 12%?

[Helge_LarsenPI-redaktør]

Jeps Bulder.

[Plimsoller]

Glofitamab.

[Plimsoller]

Gennembrud i kræftbehandling: »På mindre end et døgn svandt tumorerne ind og blev bløde«

B.T. (www.bt.dk)

[Solsen]

Mærkeligt at jeg ikke kan finde hexa-cd38 på CT. Men på EUs liste https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003781-40/SE

[E_L]

the question on Tisotumab Vedotin was not very precise, but i think Jan is referring to peak sales for cervical cancer there; that amount could get much higher if it works in other indications

[Solsen]

I linket som plimsoller lagde op er endnu et link, hvor bispecifikke i solide omtales positivt. Kunne være Gen1046 https://sundhedspolitisktidsskrift.dk/nyheder/4467-behandlingsrevolution-indenfor-lymfekraeft-vi-har-set-hvordan-tumorerne-pa-mindre-end-et-dogn-svandt-ind-og-blev-helt-blode-det-er-naermest-uvirkeligt.html og bemærk at epco er med i omtalen.

[E_L]

@Solsen ; it isn't on CT yet, i also searched for it a while ago; I actually wondered if Genmab was hoping they will not have to go through the trouble and JNJ will choose to opt in soon and do it for them...

[E_L]

and on 16:41 ; it is; Hutchings is working on both Glofi and Epco

[E_L]

it is taken from the article in the 13:43 link i believe

[GeorgeBest]

Epco has the lead over glofi on safety and subcu, it might of course change if Roche a subcu version for glofi, but so far there is not clear proof of that.

[GeorgeBest]

develope a subcu version

[Solsen]

Det er nok snarere Gen1042 https://clinicaltrials.gov/ct2/show/NCT04083599?term=Gen1042&draw=2&rank=1 i tarmkræft